Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18662102 | MODULAR GENETICALLY ENGINEERED CELL AND METHODS OF GENERATION THEREOF | May 2024 | August 2025 | Allow | 15 | 1 | 1 | Yes | No |
| 18524967 | GENE THERAPY FOR AADC DEFICIENCY | November 2023 | June 2025 | Allow | 19 | 1 | 0 | No | No |
| 18518212 | ABCA4 TRANS-SPLICING MOLECULES | November 2023 | June 2025 | Allow | 19 | 3 | 2 | Yes | No |
| 18490841 | METHOD TO ENHANCE THE EFFICIENCY OF SYSTEMIC AAV GENE DELIVERY TO THE CENTRAL NERVOUS SYSTEM | October 2023 | February 2026 | Allow | 28 | 2 | 0 | No | No |
| 18486682 | Recombinant Adeno-Associated Vectors For Targeted Treatment | October 2023 | August 2025 | Abandon | 22 | 1 | 0 | No | No |
| 18223338 | MODIFIED NK-92 haNK003 CELLS FOR THE CLINIC | July 2023 | August 2025 | Allow | 25 | 2 | 0 | Yes | No |
| 18332621 | METHODS AND PRODUCTS FOR TRANSFECTING CELLS | June 2023 | April 2025 | Allow | 22 | 1 | 0 | No | No |
| 18332620 | METHODS AND PRODUCTS FOR TRANSFECTING CELLS | June 2023 | March 2025 | Allow | 22 | 1 | 0 | No | No |
| 18196192 | THYROID MANUFACTURING PROCESS AND SPECIFICATIONS | May 2023 | March 2026 | Allow | 34 | 1 | 0 | No | No |
| 18300693 | Liver-Specific Nucleic Acid Regulatory Elements and Methods and Use Thereof | April 2023 | May 2025 | Allow | 25 | 1 | 0 | No | No |
| 18188421 | METHODS FOR REPROGRAMMING CELLS AND USES THEREOF | March 2023 | October 2025 | Allow | 31 | 2 | 0 | No | No |
| 18012894 | PYRUVATE KINASE DEFICIENCY (PKD) GENE EDITING TREATMENT METHOD | December 2022 | February 2026 | Allow | 38 | 1 | 0 | No | No |
| 18068056 | GENE-EDITED NATURAL KILLER CELLS | December 2022 | March 2025 | Allow | 27 | 1 | 0 | Yes | No |
| 18074781 | NUCLEASE-MEDIATED GENOME EDITING OF PRIMARY CELLS AND RELATED KITS | December 2022 | December 2025 | Allow | 36 | 1 | 0 | No | No |
| 18058457 | ADENO-ASSOCIATED VIRUS VECTORS ENCODING MODIFIED G6PC AND USES THEREOF | November 2022 | June 2025 | Allow | 30 | 2 | 0 | Yes | No |
| 18057912 | Methods for monitoring physiological status of a body organ | November 2022 | December 2025 | Allow | 36 | 2 | 1 | No | No |
| 17971677 | MEDIA FOR CULTURING STEM CELLS | October 2022 | May 2025 | Allow | 31 | 1 | 0 | Yes | No |
| 18047673 | TRANSGENIC MICE | October 2022 | May 2025 | Abandon | 30 | 0 | 1 | No | No |
| 17958816 | METHODS AND PRODUCTS FOR TRANSFECTION | October 2022 | July 2024 | Allow | 22 | 1 | 0 | No | No |
| 17957598 | THERAPY FOR POLYGLUTAMINE (POLYQ) DISEASES | September 2022 | March 2024 | Allow | 17 | 1 | 0 | No | No |
| 17916308 | DUAL AAV-MYO7A VECTORS WITH IMPROVED SAFETY FOR THE TREATMENT OF USH1B | September 2022 | March 2025 | Allow | 30 | 3 | 1 | Yes | No |
| 17947846 | MICROFLUIDIC DEVICE, SYSTEM AND METHODS THEREOF FOR MEASURING AND RECORDING ELECTRICAL SIGNALS FROM A POOL OF MULTIPLE NEMATODES | September 2022 | March 2025 | Abandon | 30 | 0 | 1 | No | No |
| 17823897 | RNA-GUIDED NUCLEASES AND ACTIVE FRAGMENTS AND VARIANTS THEREOF AND METHODS OF USE | August 2022 | August 2023 | Allow | 11 | 0 | 1 | Yes | No |
| 17898360 | METHODS FOR REPROGRAMMING SOMATIC CELLS | August 2022 | March 2023 | Allow | 7 | 1 | 0 | No | No |
| 17821298 | METHODS AND PRODUCTS FOR TRANSFECTING CELLS | August 2022 | November 2024 | Abandon | 27 | 1 | 0 | Yes | No |
| 17819539 | ONE-STEP METHOD FOR PRODUCING ADENOVIRAL VECTORS | August 2022 | March 2026 | Allow | 43 | 2 | 0 | No | No |
| 17817966 | METHODS AND PRODUCTS FOR TRANSFECTING CELLS | August 2022 | August 2024 | Allow | 24 | 1 | 0 | No | No |
| 17816367 | Adeno-Associated Virus-Mediated CRISPR-Cas9 Treatment of Ocular Disease | July 2022 | February 2026 | Abandon | 43 | 1 | 1 | No | No |
| 17796064 | GENE THERAPY FOR TREATING CDKL5 DEFICIENCY DISORDER | July 2022 | January 2026 | Allow | 42 | 1 | 0 | No | No |
| 17793150 | MODULATING TLR/NF-KB AND P53 SIGNALING PATHWAYS TO ENHANCE INTERSPECIES CHIMERISM BETWEEN EVOLUTIONARYILY DISTANT SPECIES | July 2022 | March 2026 | Allow | 44 | 2 | 1 | No | No |
| 17805825 | DETARGETED ADENOVIRUS VARIANTS AND RELATED METHODS | June 2022 | August 2024 | Abandon | 27 | 1 | 0 | No | No |
| 17750705 | COMPOSITIONS AND METHODS FOR IMPROVING VIRAL VECTOR EFFICIENCY | May 2022 | April 2025 | Abandon | 34 | 0 | 1 | No | No |
| 17741666 | LACTAM-MODIFIED ADENO-ASSOCIATED VIRUS VECTORS | May 2022 | October 2025 | Allow | 41 | 1 | 1 | Yes | No |
| 17776100 | METHOD FOR DIRECT TRANSDIFFERENTIATION OF SOMATIC CELL | May 2022 | December 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17775016 | GENERATION OF ENGINEERED REGULATORY T CELLS | May 2022 | November 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17732901 | Adeno-Associated Virus Virions for Treatment of Epilepsy | April 2022 | November 2024 | Allow | 31 | 2 | 0 | No | No |
| 17730099 | ISOLATION AND CULTIVATION OF MUSCLE AND FAT CELLS FROM CRUSTACEANS | April 2022 | September 2024 | Abandon | 29 | 4 | 1 | Yes | No |
| 17712785 | METHODS OF DIFFERENTIATING STEM CELL-DERIVED ECTODERMAL LINEAGE PRECURSORS | April 2022 | December 2023 | Allow | 20 | 1 | 0 | No | No |
| 17703762 | NON-TOXIC HSV VECTORS FOR EFFICIENT GENE DELIVERY APPLICATIONS AND COMPLEMENTING CELLS FOR THEIR PRODUCTION | March 2022 | November 2024 | Abandon | 32 | 4 | 1 | Yes | No |
| 17638905 | BIODEGRADABLE SOFT ELASTOMERS FOR REGENERATIVE ENGINEERING | February 2022 | February 2026 | Allow | 47 | 1 | 1 | No | No |
| 17678934 | TARGETED DISRUPTION OF THE MHC CELL RECEPTOR | February 2022 | February 2026 | Abandon | 47 | 0 | 1 | No | No |
| 17559314 | METHOD OF NOCICEPTOR DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS AND USES THEREOF | December 2021 | September 2024 | Abandon | 33 | 0 | 1 | No | No |
| 17553697 | RETROVIRAL VECTOR HAVING IMMUNE-STIMULATING ACTIVITY | December 2021 | August 2024 | Abandon | 32 | 1 | 0 | No | No |
| 17619165 | NOVEL CRISPR DNA TARGETING ENZYMES AND SYSTEMS | December 2021 | October 2025 | Abandon | 47 | 0 | 1 | No | No |
| 17538699 | GENE-EDITED NATURAL KILLER CELLS | November 2021 | September 2022 | Allow | 10 | 1 | 1 | Yes | No |
| 17610661 | GMCI AND DDRI COMBINATION THERAPY FOR TREATING CANCER | November 2021 | October 2025 | Abandon | 47 | 0 | 1 | No | No |
| 17502421 | NUCLEASE-MEDIATED GENOME EDITING OF PRIMARY CELLS | October 2021 | March 2022 | Allow | 5 | 1 | 0 | Yes | No |
| 17502479 | PHARMACEUTICAL COMPOSITIONS COMPRISING GENE-CORRECTED PRIMARY CELLS | October 2021 | December 2022 | Allow | 14 | 2 | 1 | Yes | No |
| 17502402 | NUCLEASE-MEDIATED GENOME EDITING OF PRIMARY CELLS AND RELATED METHODS OF TREATMENT | October 2021 | February 2023 | Abandon | 16 | 2 | 1 | No | No |
| 17495087 | METHOD FOR DEVELOPING ORGAN THAT LACKS SPECIFIC FUNCTIONAL CELL | October 2021 | April 2025 | Abandon | 42 | 2 | 1 | Yes | No |
| 17449015 | OVARIAN FOLLICLE CELLS AND CONSTRUCTS FOR FERTILITY TREATMENT AND HORMONE REPLACEMENT THERAPY | September 2021 | November 2025 | Allow | 50 | 2 | 1 | No | No |
| 17469441 | CARDIOSPHERE-DERIVED CELLS AND EXOSOMES SECRETED BY SUCH CELLS IN THE TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION | September 2021 | August 2023 | Allow | 23 | 1 | 0 | No | No |
| 17463690 | Process of Using a Fish Plasma Component in a Nutrient Medium for Cell Culture | September 2021 | December 2022 | Abandon | 15 | 2 | 1 | No | No |
| 17458609 | Compositions And Methods For Differentiation Of Human Pluripotent Stem Cells Into Desired Cell Types | August 2021 | June 2024 | Allow | 33 | 2 | 1 | Yes | No |
| 17433577 | AUGMENTATIONS TO LENTIVIRAL VECTORS (CCLC-MGATA/ANK-CORE LCR-BETA-AS3-FB) TO INCREASE EXPRESSION | August 2021 | January 2026 | Allow | 53 | 2 | 1 | No | No |
| 17407718 | AAV-IDUA VECTOR FOR TREATMENT OF MPS I-ASSOCIATED BLINDNESS | August 2021 | September 2024 | Allow | 37 | 2 | 1 | No | No |
| 17402543 | PORCINE THY1 GENE PROMOTER SPECIFICALLY EXPRESSED IN NEURONS | August 2021 | July 2023 | Allow | 23 | 1 | 0 | No | No |
| 17383019 | METHODS FOR REPROGRAMING NON-PLURIPOTENT CELLS INTO PLURIPOTENT STEM CELLS | July 2021 | June 2024 | Allow | 35 | 2 | 0 | Yes | No |
| 17425043 | CHOROID PLEXUS ORGANOIDS AND METHODS FOR PRODUCTION THEREOF | July 2021 | April 2025 | Allow | 45 | 1 | 1 | No | No |
| 17422596 | ISOLATION AND CULTIVATION OF MUSCLE AND FAT CELLS FROM CRUSTACEANS | July 2021 | November 2025 | Abandon | 52 | 2 | 1 | No | No |
| 17363546 | COMPOSITIONS, SYSTEMS, AND METHODS FOR BASE DIVERSIFICATION | June 2021 | May 2024 | Allow | 35 | 1 | 1 | No | No |
| 17417829 | ANTHELMINTIC LABORATORY ANIMAL MODEL FOR HEARTWORM | June 2021 | March 2025 | Abandon | 45 | 2 | 1 | Yes | No |
| 17348907 | NON-HUMAN ANIMALS MODELS OF RETINOSCHISIS | June 2021 | May 2024 | Allow | 35 | 2 | 0 | Yes | No |
| 17320676 | INDUCTION OF PLURIPOTENT CELLS | May 2021 | August 2024 | Allow | 39 | 1 | 1 | No | No |
| 17288379 | MODIFIED CAS9 PROTEIN, AND USE THEREOF | April 2021 | February 2025 | Abandon | 46 | 0 | 1 | No | No |
| 17285430 | METHOD OF OVEREXPRESSING TARGET GENE USING ELECTROMAGNETIC WAVE-REACTIVE PROMOTER | April 2021 | August 2025 | Allow | 52 | 2 | 1 | Yes | No |
| 17282097 | GENETICALLY MODIFIED SALMON WHICH PRODUCE STERILE OFFSPRING | April 2021 | August 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17208477 | CRISPR-BASED GENOME MODIFICATION AND REGULATION | March 2021 | November 2024 | Abandon | 44 | 1 | 0 | No | No |
| 17276090 | COMPOSITION FOR INDUCING DEATH OF CELLS HAVING MUTATED GENE, AND METHOD FOR INDUCING DEATH OF CELLS HAVING MUTATED GENE BY USING COMPOSITION | March 2021 | February 2026 | Abandon | 59 | 2 | 1 | No | No |
| 17198505 | USE OF PRE T ALPHA OR FUNCTIONAL VARIANT THEREOF FOR EXPANDING TCR ALPHA DEFICIENT T CELLS | March 2021 | January 2022 | Allow | 11 | 3 | 0 | Yes | No |
| 17186877 | METHOD FOR PRODUCING NATURAL KILLER CELLS FROM PLURIPOTENT STEM CELLS | February 2021 | March 2025 | Allow | 49 | 3 | 1 | Yes | No |
| 17180585 | ENHANCED IMMUNE EFFECTOR CELLS AND USE THEREOF | February 2021 | February 2022 | Allow | 12 | 2 | 1 | Yes | No |
| 17157745 | GENE THERAPY FOR AADC DEFICIENCY | January 2021 | August 2023 | Allow | 31 | 2 | 0 | Yes | No |
| 17146200 | ENHANCED IMMUNE EFFECTOR CELLS AND USE THEREOF | January 2021 | September 2024 | Allow | 44 | 2 | 1 | No | No |
| 17125449 | FRATAXIN EXPRESSION CONSTRUCTS | December 2020 | January 2024 | Allow | 37 | 2 | 0 | No | No |
| 17253518 | METHOD OF DIFFERENTIATING PRIMORDIAL GERM CELL INTO PRIMORDIAL FOLLICLE IN VITRO | December 2020 | March 2024 | Allow | 39 | 2 | 0 | Yes | No |
| 17118981 | HUMANIZED HEART MUSCLE | December 2020 | February 2025 | Abandon | 50 | 2 | 1 | No | No |
| 17118064 | NON-MEIOTIC ALLELE INTROGRESSION | December 2020 | January 2024 | Abandon | 38 | 1 | 1 | No | No |
| 16952807 | HUMANIZED SKELETAL MUSCLE | November 2020 | May 2024 | Allow | 42 | 2 | 0 | No | No |
| 17091203 | Methods for the Treatment and Diagnosis of Alzheimer's Disease and Traumatic Brain Injuries | November 2020 | August 2024 | Abandon | 45 | 2 | 1 | No | No |
| 17086072 | METHOD OF PRODUCING RECOMBINANT HIGH MOLECULAR WEIGHT vWF IN CELL CULTURE | October 2020 | June 2023 | Allow | 31 | 1 | 0 | Yes | No |
| 17065541 | Method For Differentiating Pluripotent Stem Cells Into Desired Cell Type | October 2020 | September 2023 | Allow | 36 | 1 | 0 | No | No |
| 17039006 | CELL CULTURE PLATFORM FOR SINGLE CELL SORTING AND ENHANCED REPROGRAMMING OF IPSCS | September 2020 | May 2025 | Allow | 56 | 4 | 1 | Yes | No |
| 17034009 | METHOD FOR CHANGING CONDITION OF EYELID OF HAIRLESS ANIMAL | September 2020 | October 2025 | Allow | 60 | 4 | 1 | No | No |
| 17040818 | Gene Editing for Autosomal Dominant Diseases | September 2020 | May 2025 | Abandon | 55 | 1 | 1 | No | No |
| 17019126 | SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | September 2020 | September 2025 | Abandon | 60 | 2 | 1 | No | No |
| 16937370 | MODIFIED NK-92 haNK003 CELLS FOR THE CLINIC | July 2020 | April 2023 | Allow | 33 | 1 | 0 | Yes | No |
| 16925518 | IN VITRO PRODUCTION OF EXPANDED POTENTIAL STEM CELLS | July 2020 | November 2023 | Allow | 40 | 1 | 1 | No | No |
| 16913306 | METHODS AND PRODUCTS FOR TRANSFECTING CELLS | June 2020 | May 2023 | Allow | 34 | 1 | 0 | No | No |
| 16913315 | METHODS AND PRODUCTS FOR TRANSFECTING CELLS | June 2020 | May 2023 | Allow | 35 | 1 | 0 | No | No |
| 16902368 | METHODS FOR PRODUCING HEPATOCYTES | June 2020 | March 2023 | Allow | 33 | 1 | 0 | No | No |
| 16895732 | EXTRACELLULAR MATRIX COMPOSITIONS FOR THE TREATMENT OF CANCER | June 2020 | July 2023 | Abandon | 37 | 1 | 0 | No | No |
| 16890697 | PHARMACEUTICAL COMPOSITION COMPRISING AIMP2-DX2 FOR PREVENTING OR TREATING NEURONAL DISEASES AND USE THEREOF | June 2020 | June 2024 | Allow | 49 | 3 | 0 | Yes | No |
| 16869394 | STEM CELL COMPOSITIONS FOR COSMETIC AND DERMATOLOGIC USE | May 2020 | May 2023 | Abandon | 36 | 1 | 0 | No | No |
| 16869232 | METHODS AND PRODUCTS FOR TRANSFECTING CELLS | May 2020 | February 2021 | Allow | 10 | 1 | 0 | Yes | No |
| 16864774 | ADIPONECTIN-EXPRESSING REGULATORY T-CELL PRECURSORS, COMPOSITION AND METHODS THEREOF | May 2020 | February 2026 | Abandon | 60 | 5 | 1 | Yes | No |
| 16857894 | METHODS AND PRODUCTS FOR TRANSFECTING CELLS | April 2020 | September 2020 | Allow | 5 | 1 | 0 | No | No |
| 16757811 | COMPOSITIONS AND METHODS USEFUL IN REGENERATIVE MEDICINE | April 2020 | August 2024 | Allow | 52 | 6 | 1 | Yes | No |
| 16811086 | STEM CELL-DERIVED SERTOLI-LIKE CELL, PREPARATION METHOD THEREFOR, AND USE THEREOF | March 2020 | June 2024 | Allow | 51 | 4 | 1 | Yes | No |
| 16808170 | METHOD FOR PREPARATION OF RETINAL GANGLION CELLS | March 2020 | February 2024 | Allow | 48 | 4 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner NOBLE, MARCIA STEPHENS.
With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 17.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner NOBLE, MARCIA STEPHENS works in Art Unit 1632 and has examined 944 patent applications in our dataset. With an allowance rate of 60.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 35 months.
Examiner NOBLE, MARCIA STEPHENS's allowance rate of 60.0% places them in the 20% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by NOBLE, MARCIA STEPHENS receive 2.25 office actions before reaching final disposition. This places the examiner in the 63% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by NOBLE, MARCIA STEPHENS is 35 months. This places the examiner in the 38% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +48.9% benefit to allowance rate for applications examined by NOBLE, MARCIA STEPHENS. This interview benefit is in the 92% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 21.5% of applications are subsequently allowed. This success rate is in the 25% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 41.3% of cases where such amendments are filed. This entry rate is in the 63% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 50.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 42% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 88.0% of appeals filed. This is in the 81% percentile among all examiners. Of these withdrawals, 81.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 69.7% are granted (fully or in part). This grant rate is in the 77% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 6.2% of allowed cases (in the 88% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.